Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein‐Mediated Drug‐Drug Interactions in Healthy Volunteers

Endogenous biomarkers are emerging to advance clinical drug‐drug interaction (DDI) risk assessment in drug development. Twelve healthy subjects received a multidrug and toxin exclusion protein (MATE) inhibitor (pyrimethamine, 10, 25, and 75 mg) in a crossover fashion to identify an appropriate endog...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyake, Takeshi, Kimoto, Emi, Luo, Lina, Mathialagan, Sumathy, Horlbogen, Lauren M., Ramanathan, Ragu, Wood, Linda S., Johnson, Jillian G., Le, Vu H., Vourvahis, Manoli, Rodrigues, A. David, Muto, Chieko, Furihata, Kenichi, Sugiyama, Yuichi, Kusuhara, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891601/
https://www.ncbi.nlm.nih.gov/pubmed/32866300
http://dx.doi.org/10.1002/cpt.2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891601/
https://www.ncbi.nlm.nih.gov/pubmed/32866300
http://dx.doi.org/10.1002/cpt.2022

Ejemplares similares